620 related articles for article (PubMed ID: 31355677)
1. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
[No Abstract] [Full Text] [Related]
2. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
4. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
[TBL] [Abstract][Full Text] [Related]
5. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
6. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
Wang CP; Young G; Thornburg CD
Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
11. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
13. RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Jain N; Lethagen S
Curr Med Res Opin; 2020 Jul; 36(7):1125-1127. PubMed ID: 32253943
[No Abstract] [Full Text] [Related]
14. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
[TBL] [Abstract][Full Text] [Related]
15. Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2020 Jul; 36(7):1129-1130. PubMed ID: 32180474
[No Abstract] [Full Text] [Related]
16. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
17. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN
Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955
[TBL] [Abstract][Full Text] [Related]
18. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
19. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab for hemophilia A without inhibitors.
Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
